Shahrokh Shariat receives Plus Ratio Quam Vis Medal from Jagiellonian University

- EN - DE
Bild: Anna Wojnar
Bild: Anna Wojnar

Shahrokh Shariat, Head of the Department of Urology and the Comprehensive Cancer Center of MedUni Vienna and Vienna General Hospital, has been awarded the Plus-ratio-quam-vis Gold Medal by the Jagiellonian University in Krakow. The award was presented at a ceremony at the university in Krakow to mark the anniversary of the university’s Faculty of Medicine.

The Rector of the Jagiellonian University honors people who have rendered outstanding services to the university with the Plus ratio quam vis commemorative medal. The motto Plus ratio quam vis (Latin: reason before force) is engraved on the portal from the Assembly Hall to the Copernicus Room in the Collegium Maius and comes from the poem "Elegy" by the 6th century poet Maximianus.

In his speech, the university’s president commended Shahrokh Shariat for his efforts in spreading scientific knowledge and establishing numerous collaborative partnerships to promote medical education across Central Europe. Shahrokh Shariat emphasized the benefits and goals of international collaboration in science and medicine. He noted that such partnerships foster innovation, enhance the quality of research, and lead to more effective healthcare solutions. By working together, countries can pool resources, share expertise, and tackle global health challenges more efficiently. Additionally, these collaborations help to break down cultural barriers, encouraging a more inclusive and diverse scientific community.
However, Shahrokh Shariat also acknowledged several barriers to empowering the next generation of leaders in Central Europe. These include limited funding for research and education and the need to address brain drain. To overcome these challenges, he advocated for increased investment in education and research, policy reforms to streamline international cooperation, and initiatives to retain and attract talent within the region.

During his visit, Shahrokh Shariat met with several faculty members and students from the university’s medical school. They engaged in cordial conversations about enhancing medical education, science, and innovation in Central Europe, exploring ways to empower future leaders in the region.

About the person:

Shahrokh Shariat, born in Tehran, is a distinguished Professor and Head of the Department of Urology as well as the head of the Comprehensive Cancer Center at the Medical University of Vienna and University Hospital Vienna. He also holds the position of Associate Professor of Urology and Oncology at Weill Cornell Medical Center in New York, NY, Associate Professor of Urology at the University of Texas Southwestern Medical Center in Dallas, TX, Associate Professor of Urology at the Faculty of Medicine, Charles University in Prague, CZ, and Honorary Professor of Urology at the University of Jordan in Amman, JO. Furthermore, he has been awarded the title of Doctor honoris causa by both Carol Davila University of Medicine and Pharmacy in Bucharest, RO, and Semmelweis University in Budapest, HU.

Shahrokh Shariat has an impressive body of work, having published over 2000 peer-reviewed publications, with a Scopus h-index of 131 and a Google h-index of 155. He has also contributed to 35 book chapters, holds four patents, and has received numerous national and international awards. Among these accolades are the prestigious Matula Award from the European Urological Association and the Gold Cystoscope from the American Urological Association. He is an active member of 25 academic societies and serves on the editorial board of 26 scientific journals. Dr. Shariat currently leads several collaborative multicenter groups and prospective clinical trials.

In addition to his academic and clinical work, Shahrokh Shariat heads a medical aid organization for refugees and serves on the medical advisory board of two other aid organizations. His research interests are primarily focused on prostate and bladder cancer, particularly in the areas of molecular mechanisms, biomarkers, early detection, translational research, and outcomes research.